Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, McNeill M, Amaravadi L, Sweetser M, Elkins J, O'Neill G; SELECTION Study Investigators. Giovannoni G, et al. Among authors: sweetser m. Lancet Neurol. 2014 May;13(5):472-81. doi: 10.1016/S1474-4422(14)70039-0. Epub 2014 Mar 19. Lancet Neurol. 2014. PMID: 24656609 Clinical Trial.
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators. Fox RJ, et al. Among authors: sweetser mt. N Engl J Med. 2012 Sep 20;367(12):1087-97. doi: 10.1056/NEJMoa1206328. N Engl J Med. 2012. PMID: 22992072 Free article. Clinical Trial.
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT; DEFINE Study Investigators. Gold R, et al. Among authors: sweetser mt. N Engl J Med. 2012 Sep 20;367(12):1098-107. doi: 10.1056/NEJMoa1114287. N Engl J Med. 2012. PMID: 22992073 Free article. Clinical Trial.
Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97.
Havrdova E, Hutchinson M, Kurukulasuriya NC, Raghupathi K, Sweetser MT, Dawson KT, Gold R. Havrdova E, et al. Among authors: sweetser mt. Expert Opin Pharmacother. 2013 Oct;14(15):2145-56. doi: 10.1517/14656566.2013.826190. Epub 2013 Aug 24. Expert Opin Pharmacother. 2013. PMID: 23971970
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, Kaufman M, Rose J, Greenberg S, Sweetser M, Riester K, O'Neill G, Elkins J. Kappos L, et al. Among authors: sweetser m. N Engl J Med. 2015 Oct 8;373(15):1418-28. doi: 10.1056/NEJMoa1501481. N Engl J Med. 2015. PMID: 26444729 Free article. Clinical Trial.
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience.
Gold R, Phillips JT, Havrdova E, Bar-Or A, Kappos L, Kim N, Thullen T, Valencia P, Oliva L, Novas M, Li J, Sweetser MT, Kurukulasuriya N, Viglietta V, Fox RJ. Gold R, et al. Among authors: sweetser mt. Neurol Ther. 2015 Dec;4(2):93-104. doi: 10.1007/s40120-015-0033-1. Epub 2015 Oct 12. Neurol Ther. 2015. PMID: 26662361 Free PMC article.
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.
Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, Havrdova E, MacManus DG, Yousry TA, Pozzilli C, Selmaj K, Sweetser MT, Zhang R, Yang M, Potts J, Novas M, Miller DH, Kurukulasuriya NC, Fox RJ, Phillips TJ. Gold R, et al. Among authors: sweetser mt. Mult Scler. 2017 Feb;23(2):253-265. doi: 10.1177/1352458516649037. Epub 2016 Jul 11. Mult Scler. 2017. PMID: 27207449 Free PMC article. Clinical Trial.
Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.
Krueger JG, Kircik L, Hougeir F, Friedman A, You X, Lucas N, Greenberg SJ, Sweetser M, Castro-Borrero W, McCroskery P, Elkins J. Krueger JG, et al. Among authors: sweetser m. Adv Ther. 2016 Jul;33(7):1231-45. doi: 10.1007/s12325-016-0353-2. Epub 2016 Jun 1. Adv Ther. 2016. PMID: 27251051 Free PMC article. Clinical Trial.
Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies.
Giovannoni G, Kappos L, Gold R, Khatri BO, Selmaj K, Umans K, Greenberg SJ, Sweetser M, Elkins J, McCroskery P. Giovannoni G, et al. Among authors: sweetser m. Mult Scler Relat Disord. 2016 Sep;9:36-46. doi: 10.1016/j.msard.2016.05.010. Epub 2016 May 11. Mult Scler Relat Disord. 2016. PMID: 27645341 Free article. Clinical Trial.
55 results